Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan

Journal of Hypertension
Jinliang LiuKenji Ueshima

Abstract

During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan. We conducted a post-trial study, the Candesartan Antihypertensive Survival Evaluation in Japan 10-year follow-up (CASE-J 10). This study aimed to confirm the long-term cardiovascular effects of candesartan and amlodipine. Case report forms were sent to CASE-J investigators who agreed to participate in the CASE-J 10. All the available information was retrospectively collected. The primary endpoint was a time-to-first event for a composite of cerebrovascular, cardiac, renal, and vascular events, and sudden death. Secondary endpoints included new-onset diabetes (NOD), cardiovascular mortality, and all-cause mortality. For each endpoint, treatment effect was compared on an intention-to-treat basis, according to previous randomization categories. A total of 1313 patients' data have been updated. The 10-year Kaplan-Meier rates of the primary endpoint were 14.7% for candesartan and 14.8% for amlodipine. After adjusting for baseline characteristics, the rates for the primary endpoint were similar between the two treatments (hazards rat...Continue Reading

References

Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Jan 14, 2004·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tsuguya FukuiUNKNOWN CASE-J Study Group
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
Nov 18, 2006·Expert Opinion on Pharmacotherapy·Philip R Liebson
Apr 10, 2007·Lancet·Roland E SchmiederBernhard M W Schmidt
Sep 12, 2007·The American Journal of Cardiology·Thomas Unger, Martina Stoppelhaar
Sep 13, 2007·Clinical Trials : Journal of the Society for Clinical Trials·Mizuki YoshidaUNKNOWN MEGA Study Group
Jan 4, 2008·Hypertension·Toshio OgiharaUNKNOWN Candesartan Antihypertensive Survival Evaluation in Japan Trial Group
May 20, 2009·Journal of Hypertension·Pierluigi CostanzoMassimo Chiariello
Dec 24, 2015·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.